Nabriva Corporate
Go to...
  • Home
  • About Nabriva
    • Our Products
    • Named Patient Program
    • Meet the Team
  • pipeline & research
    • Fosfomycin
    • pleuromutilins
  • For Investors
    • Events & Presentations
    • Press Releases
    • Financial Performance
    • Share Performance
    • Shareholder Information
    • Corporate Governance
  • News & Publications
  • careers
  • contact us
  • News & Publications
  • Careers
  • Contact Us
Nabriva Corporate
  • Home
  • About Nabriva
    • Our Products
    • Named Patient Program
    • Meet the Team
  • pipeline & research
    • Fosfomycin
    • pleuromutilins
  • For Investors
    • Events & Presentations
    • Press Releases
    • Financial Performance
    • Share Performance
    • Shareholder Information
    • Corporate Governance
  • News & Publications
  • careers
  • contact us

contact us

Home / contact us

Medical Information

For Product information or to report an adverse event, product quality complaint, or exposure to XENLETA during pregnancy:


1-855-5NABRIVA, Press 1 (MON-FRI:9AM-5PM EST)

Medical.Information@Nabriva.com

Suspected adverse events may be reported to the FDA directly

1-800-FDA-1088 or www.fda.gov/medwatch

Nabriva Therapeutics US, Inc.

1000 Continental Drive, Suite 600
King of Prussia, PA 19406
USA

View Google map

T +1 (610) 816-6640

F +1 (610) 816-6639

officeUS@nabriva.com

Nabriva Therapeutics GmbH

Leberstrasse 20
1110 Vienna
Austria

View Google map

T +43 (0)1 740 93-0

F +43 (0)1 740 93-1900

office@nabriva.com

FN 269261 Y

VAT No.: ATU62319422

Nabriva Therapeutics plc

25-28 North Wall Quay,
IFSC, Dublin 1, Ireland

T +353 1 649 2000

officeIE@nabriva.com

 

Nabriva Therapeutics Ireland DAC

Alexandra House, Office 225/227
The Sweepstakes
Ballsbridge
Dublin 4
D04 C7H2
Republic of Ireland

View Google map

T +353 (0) 1 664 1700

officeIE@nabriva.com

VAT No. 3514827BH

Reg. No. 612454

 

Press Contact

PR@nabriva.com

Business Development Contact

BD@nabriva.com

 

 

 

Nabriva Response to COVID-19

Thank you to all the healthcare professionals for your tireless service on the frontlines of this pandemic.  Due to COVID-19, the FDA has reported shortages of key drugs, including select antibiotics.  XenletaTM (lefamulin) may be an alternative regimen for patients in need.  Nabriva wants to reassure you that we have sufficient inventory of XENLETA IV and Oral tablets, available through designated specialty pharmacies or specialty distributors.  Learn more at www.XENLETA.com.

Again, to all the medical professionals, please be safe, take care of yourself and stay well.

Best,
Ted Schroeder
CEO, Nabriva Therapeutics

Continue to site

Nabriva logo
  • Privacy Notice
  • Patents
  • Imprint
  • Disclaimer
  • Contact Us
  • Careers
  • Sitemap

© Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland

  • Privacy Notice
  • Patents
  • Imprint
  • Disclaimer
  • Contact Us
  • Careers
  • Sitemap
Nabriva logo

© Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland